Insider Selling: Belite Bio (NASDAQ:BLTE) CFO Sells $66,188.45 in Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CFO Hao-Yuan Chuang sold 367 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total value of $66,188.45. Following the completion of the transaction, the chief financial officer directly owned 93,433 shares of the company’s stock, valued at approximately $16,850,641.55. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Belite Bio Stock Performance

Shares of BLTE stock opened at $162.80 on Monday. The stock has a 50 day moving average of $152.50 and a two-hundred day moving average of $159.85. Belite Bio, Inc. Sponsored ADR has a 12 month low of $60.00 and a 12 month high of $200.00. The company has a market capitalization of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. Sell-side analysts predict that Belite Bio, Inc. Sponsored ADR will post -3.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Belite Bio

Institutional investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC raised its stake in shares of Belite Bio by 225.0% in the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock valued at $10,364,000 after acquiring an additional 45,000 shares during the last quarter. Western Standard LLC acquired a new position in shares of Belite Bio in the 4th quarter worth approximately $9,602,000. The Manufacturers Life Insurance Company bought a new stake in Belite Bio during the 1st quarter worth approximately $3,125,000. Renaissance Technologies LLC bought a new stake in Belite Bio during the 1st quarter worth approximately $8,291,000. Finally, Eventide Asset Management LLC increased its holdings in Belite Bio by 96.1% during the 4th quarter. Eventide Asset Management LLC now owns 383,091 shares of the company’s stock valued at $61,279,000 after purchasing an additional 187,779 shares in the last quarter. 0.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Belite Bio in a report on Monday, July 6th. Truist Financial set a $217.00 price objective on shares of Belite Bio in a report on Friday, May 22nd. HC Wainwright lifted their target price on shares of Belite Bio from $200.00 to $214.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Cantor Fitzgerald upped their target price on shares of Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Morgan Stanley increased their price target on shares of Belite Bio from $201.00 to $206.00 and gave the stock an “overweight” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $205.80.

Belite Bio News Roundup

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.